Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Despite the clear benefits demonstrated by immunotherapy, there is still an inevitable off-target effect resulting in serious adverse immune reactions. In recent years, the research and development of Drug Delivery System (DDS) has received increased prominence. In decades of development, DDS has de...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1328145/full |
| _version_ | 1797353585998036992 |
|---|---|
| author | Xu Liu Yang Cheng Yao Mu Zhaohan Zhang Dan Tian Yunpeng Liu Yunpeng Liu Yunpeng Liu Yunpeng Liu Xuejun Hu Ti Wen Ti Wen Ti Wen Ti Wen |
| author_facet | Xu Liu Yang Cheng Yao Mu Zhaohan Zhang Dan Tian Yunpeng Liu Yunpeng Liu Yunpeng Liu Yunpeng Liu Xuejun Hu Ti Wen Ti Wen Ti Wen Ti Wen |
| author_sort | Xu Liu |
| collection | DOAJ |
| description | Despite the clear benefits demonstrated by immunotherapy, there is still an inevitable off-target effect resulting in serious adverse immune reactions. In recent years, the research and development of Drug Delivery System (DDS) has received increased prominence. In decades of development, DDS has demonstrated the ability to deliver drugs in a precisely targeted manner to mitigate side effects and has the advantages of flexible control of drug release, improved pharmacokinetics, and drug distribution. Therefore, we consider that combining cancer immunotherapy with DDS can enhance the anti-tumor ability. In this paper, we provide an overview of the latest drug delivery strategies in cancer immunotherapy and briefly introduce the characteristics of DDS based on nano-carriers (liposomes, polymer nano-micelles, mesoporous silica, extracellular vesicles, etc.) and coupling technology (ADCs, PDCs and targeted protein degradation). Our aim is to show readers a variety of drug delivery platforms under different immune mechanisms, and analyze their advantages and limitations, to provide more superior and accurate targeting strategies for cancer immunotherapy. |
| first_indexed | 2024-03-08T13:33:09Z |
| format | Article |
| id | doaj.art-2cf955fcbb154681ab4d669a3d5e82c2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T13:33:09Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2cf955fcbb154681ab4d669a3d5e82c22024-01-17T04:24:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011510.3389/fimmu.2024.13281451328145Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overviewXu Liu0Yang Cheng1Yao Mu2Zhaohan Zhang3Dan Tian4Yunpeng Liu5Yunpeng Liu6Yunpeng Liu7Yunpeng Liu8Xuejun Hu9Ti Wen10Ti Wen11Ti Wen12Ti Wen13Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaNo.20 High School, Shenyang, Liaoning, ChinaDepartment of Thoracic Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaClinical Cancer Treatment and Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaClinical Cancer Treatment and Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDespite the clear benefits demonstrated by immunotherapy, there is still an inevitable off-target effect resulting in serious adverse immune reactions. In recent years, the research and development of Drug Delivery System (DDS) has received increased prominence. In decades of development, DDS has demonstrated the ability to deliver drugs in a precisely targeted manner to mitigate side effects and has the advantages of flexible control of drug release, improved pharmacokinetics, and drug distribution. Therefore, we consider that combining cancer immunotherapy with DDS can enhance the anti-tumor ability. In this paper, we provide an overview of the latest drug delivery strategies in cancer immunotherapy and briefly introduce the characteristics of DDS based on nano-carriers (liposomes, polymer nano-micelles, mesoporous silica, extracellular vesicles, etc.) and coupling technology (ADCs, PDCs and targeted protein degradation). Our aim is to show readers a variety of drug delivery platforms under different immune mechanisms, and analyze their advantages and limitations, to provide more superior and accurate targeting strategies for cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1328145/fullcancer immunotherapydrug deliverynanoparticlescoupled drugsprotein degradationmultidrug combination |
| spellingShingle | Xu Liu Yang Cheng Yao Mu Zhaohan Zhang Dan Tian Yunpeng Liu Yunpeng Liu Yunpeng Liu Yunpeng Liu Xuejun Hu Ti Wen Ti Wen Ti Wen Ti Wen Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview Frontiers in Immunology cancer immunotherapy drug delivery nanoparticles coupled drugs protein degradation multidrug combination |
| title | Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview |
| title_full | Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview |
| title_fullStr | Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview |
| title_full_unstemmed | Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview |
| title_short | Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview |
| title_sort | diverse drug delivery systems for the enhancement of cancer immunotherapy an overview |
| topic | cancer immunotherapy drug delivery nanoparticles coupled drugs protein degradation multidrug combination |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1328145/full |
| work_keys_str_mv | AT xuliu diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT yangcheng diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT yaomu diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT zhaohanzhang diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT dantian diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT yunpengliu diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT yunpengliu diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT yunpengliu diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT yunpengliu diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT xuejunhu diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT tiwen diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT tiwen diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT tiwen diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview AT tiwen diversedrugdeliverysystemsfortheenhancementofcancerimmunotherapyanoverview |